A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer
(NSCLC)
- Treating physician's decision to initiate first-line Avastin treatment
Exclusion Criteria:
- Participation in a clinical trial evaluating anti-cancer therapies
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
18 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Commission Nationale de l'Informatique et des Libertés (CNIL)
Study ID:
ML22991
NCT ID:
NCT01333007
Start Date:
July 2010
Completion Date:
March 2013
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
